OpGen Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

OpGen's earnings have been declining at an average annual rate of -12.8%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been declining at an average rate of 5.6% per year.

Anahtar bilgiler

-12.8%

Kazanç büyüme oranı

57.0%

EPS büyüme oranı

Biotechs Sektör Büyümesi17.0%
Gelir büyüme oranı-5.6%
Özkaynak getirisin/a
Net Marj-1,139.7%
Son Kazanç Güncellemesi30 Jun 2024

Yakın geçmiş performans güncellemeleri

Recent updates

OpGen to raise $3.38M in direct stock offering

Sep 30

OpGen's subsidiary signs R&D agreement with FIND

Sep 20

Nasdaq grants extension to OpGen to regain compliance with minimum bid price requirement

Aug 31

OpGen launches sequencing services for infectious diseases in US

Aug 25

OpGen GAAP EPS of -$0.13 beats by $0.02, revenue of $1M in-line

Aug 11

OpGen reports preliminary revenue estimate for Q2 2022

Jul 08

OpGen gains on insider buying

Jun 15

OpGen submits 510(k) summary to FDA for Acuitas AMR Gene Panel for Isolates

Jun 07

OpGen reports prelim Q4 & FY20 revenue

Jan 13

OpGen subsidiary Curetis and Annar ink Unyvero distribution partnership for Colombia

Jan 05

OpGen launches $10M private placement

Nov 24

OpGen EPS misses by $0.04, beats on revenue

Nov 11

OpGen's subsidiary and collaborators secures German funding to develop such a molecular diagnostics platform

Oct 28

Gelir ve Gider Dağılımı

OpGen nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.


Kazanç ve Gelir Geçmişi

OTCPK:OPGN Gelir, gider ve kazançlar (USD Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
30 Jun 242-2270
31 Mar 243-2790
31 Dec 233-33110
30 Sep 233-26130
30 Jun 233-36130
31 Mar 233-36130
31 Dec 223-37130
30 Sep 223-41140
30 Jun 224-33140
31 Mar 224-34140
31 Dec 214-42140
30 Sep 214-35130
30 Jun 214-37130
31 Mar 214-37130
31 Dec 204-26120
30 Sep 204-22100
30 Jun 203-1790
31 Mar 203-1380
31 Dec 193-1280
30 Sep 193-1480
30 Jun 193-1380
31 Mar 193-1490
31 Dec 183-1390
30 Sep 183-1380
30 Jun 183-1380
31 Mar 183-1390
31 Dec 173-1590
30 Sep 173-17110
30 Jun 173-19120
31 Mar 174-20120
31 Dec 164-19120
30 Sep 164-19130
30 Jun 165-19120
31 Mar 164-19110
31 Dec 153-18100
30 Sep 153-148-3
30 Jun 153-1260
31 Mar 154-850
31 Dec 144-640
30 Sep 144-943
31 Dec 132-1660

Kaliteli Kazançlar: OPGN is currently unprofitable.

Büyüyen Kar Marjı: OPGN is currently unprofitable.


Serbest Nakit Akışı ve Kazanç Analizi


Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: OPGN is unprofitable, and losses have increased over the past 5 years at a rate of 12.8% per year.

Büyüme Hızlandırma: Unable to compare OPGN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Kazançlar vs. Sektör: OPGN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).


Özkaynak Getirisi

Yüksek ROE: OPGN's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Varlık Getirisi


Kullanılan Sermaye Getirisi


Geçmişte güçlü performans gösteren şirketleri keşfedin